Abstract
AbstractThe fight against the current Covid‐19 pandemic highlights the need for, and benefits of ‘personalized medicine’. This is driving a growing demand for more detailed analysis of disease pathology as well as patients' individual immune system characteristics and hence predicted disease progression and optimum treatment. One of the consequences is that clinical labs and research facilities are looking to increase performance and usage of multiparameter flow cytometry as a key tool to analyze the cellular components of the immune system. In response, Coherent is supporting faster instrument development and increasing the number of parameters in two ways – integrated multiwavelength OEM subsystems, and new laser wavelengths in the ultraviolet, all with output beam parameters optimized for common flow cytometry platforms.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
